Manufacturer
GLAXO OPERATIONS UK LTD
Contents
Eltrombopag olamine
Indication
Idiopathic thrombocytopenic purpura, Aplastic anaemia, Thrombocytopenia associated with chronic hepatitis C.
Instruction
Idiopathic thrombocytopenic purpura
Adult: Patient w/ inadequate response to corticosteroids and immunoglobulins or splenectomy: Initially, 50 mg once daily, adjust dose at 2 wk intervals to achieve and maintain ≥50 x 109 cells/L platelet count. Max: 75 mg daily.
Child: 1-5 yr Initially, 25 mg once daily; ≥6 yr Same as adult dose.
Aplastic anaemia
Adult: Patient w/ severe cases, unresponsive to immunosuppressive therapy and unsuitable for haematopoietic stem cell transplantation: Initially, 50 mg once daily, adjust dose in 50 mg increments 2 wk to achieve and maintain ≥50 x 109 cells/L platelet count. Max: 150 mg daily. In patient w/ tri-lineage response for 8 wk and transfusion independence, dose may be reduced by 50%.
Thrombocytopenia associated with chronic hepatitis C
Adult: Combination therapy w/ interferon: Initially, 25 mg once daily, adjust dose in increments of 25 mg every 2 wk until adequate response is achieved. Max: 100 mg daily.
Drug interaction
Decreased plasma exposure w/ ciclosporin, lopinavir-ritonavir, CYP1A2 and CYP2C8 inducers (e.g. rifampicin). Forms chelates w/ polyvalent cations (e.g. Fe, Ca, Mg, Al, selenium, Zn), resulting in decreased plasma concentration. Increased plasma concentration w/ CYP1A2 and CYP2C8 inhibitor (e.g. fluvoxamine), and rosuvastatin.Potentially Fatal: Increased risk of hepatic decompensation in patient w/ hepatitis C infection who are taking interferon and ribavirin.
Malaysia
